Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: osi-7904, capecitabine, pemetrexed disodium +7 | 1.00 |
| trials ClinicalTrials.gov | 39 Parkinson's trials, 3 stopped | 0.94 |
| literature PubMed | 3 Parkinson's papers of 951 | 0.82 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 11656
Sealed predictions
- TYMS in dopamine neurons, braak-0.59 (p 0.092) → +0.05 (p 0.889)receipt 11663
Swarm cases
receipt 11663: TYMS in dopamine neurons, braak
- power
- full sample -0.31 (p 0.207, n 18), 95% CI -0.68 to +0.18. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.31 (p 0.218, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.28 (p 0.261, n 18). could be the mix.
- skeptic
- leave-one-out range -0.43 to -0.20, sign flips 0; without severely affected donors -0.31 (p 0.207, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TYMS in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts